Qed Therapeutics, A Bridgebio Company

This study tests an oral drug called infigratinib in infants and children under 3 with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth and body proportions. About 77 children will take either the drug or a placebo, and researchers…

This study follows 150 children aged 2.5 to 17 with hypochondroplasia, a condition causing short stature. Researchers will measure height, body proportions, thinking skills, and quality of life over time. No treatment is given; the goal is to learn more about how the condition ch…